A pilot study of topiramate as monotherapy in the treatment of acute mania.
This small-scale pilot study was performed to grossly document safety and any evidence of efficacy of topiramate in bipolar disorder. Ten patients hospitalized for acute mania were given open-label topiramate monotherapy for up to 28 days. The mean Young Mania Rating Scale (YMRS) score decreased from 32 (range, 26-40) at baseline to 22 (range, 2-40) at the end of the study. Five patients exhibited evidence of moderate to marked improvement, three subjects had at least a 50% reduction in YMRS scores, and the other two patients experienced an improvement of 25% to 49% on the YMRS. The preliminary findings of this small series suggest that topiramate may be effective in acute mania. Double-blind controlled trials are now needed to further investigate the efficacy and safety of topiramate in bipolar disorder.
Calabrese
J R
JR
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. jrc8@cwru.edu
Keck
P E
PE
McElroy
S L
SL
Shelton
M D
MD
D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology; D010054:Brief Psychiatric Rating Scale / Q000706:statistics & numerical data; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D000077236:Topiramate
D014151:Anti-Anxiety Agents; D000077236:Topiramate; D005632:Fructose